Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 6,190 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly conducts its businesses within domestic and overseas markets.
Innovent Biologics Inc の最大収益セグメントは Antibody and Protein Medicine, Pharmaceutical Products and Consultation and Research and Development Services で、最新の利益発表における収益は 10,215,436,051 です。地域別に見ると、China が Innovent Biologics Inc の主要市場であり、収益は 9,740,034,234 です。